Medtronic heart device study misses main goal
Medtronic Inc said on Tuesday a study of device therapy in patients with mild heart failure missed its primary goal on a measure of disease progression, but some patients saw their conditions improve.
bdnews24.com News Service
bdnews24.com
Published :
01 Apr 2008, 02:20 PM
Updated :
24 Apr 2022, 08:22 PM
CHICAGO April 1 (bdnews24.com/Reuters) - Medtronic Inc said on Tuesday a study of device therapy in patients with mild heart failure missed its primary goal on a measure of disease progression, but some patients saw their conditions improve.
Patients in the study, called Reverse, received cardiac resynchronization therapy (CRT) via an implanted device plus medicine, or medicine alone.
The study was being presented at the American College of Cardiology meeting in Chicago.
"Despite the trial not meeting statistical significance for the pre-specified analysis of its primary endpoint of a heart failure clinical composite score at 12 months, more patients in the trial improved with CRT," Medtronic said in a news release.
On a secondary endpoint, some patients whose implanted devices were turned on to receive CRT saw improvement in cardiac function and a reduction in heart size at one year after treatment, the study's researchers said. An enlarged heart can impede efficient pumping in heart failure patients.
"I'm very convinced that CRT does stop the progression, even reverse it, in terms of shrinkage of the left ventricle," said lead author Dr. Cecilia Linde of Karolinska University Hospital in Stockholm, Sweden.
Patients on CRT also saw a decreased risk of hospitalization for their heart failure symptoms in the study, Linde said.
CRT devices are typically implanted in patients diagnosed with severe heart failure, where the heart cannot pump enough blood through the body.
The Medtronic-sponsored Reverse study of 610 patients was the first large-scale clinical trial that sought to determine whether people with mildly symptomatic heart failure could benefit from CRT therapy.
Boston Scientific Corp, which also makes CRT devices, is also studying whether CRT therapy can slow the progession of earlier-stage heart failure. Its study, called MADIT-CRT, involves 1,820 patients and is under way at the University of Rochester.
Shares of Medtronic were up 19 cents at $48.56 in morning trading on the New York Stock Exchange.
bdnews24.com/lq/2017hrs